Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
10.44 BRL | +1.00% | +2.25% | -36.32% |
Mar. 20 | Transcript : Blau Farmacêutica S.A., Q4 2023 Earnings Call, Mar 20, 2024 | |
Mar. 19 | Blau Farmacêutica S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 1.6B 316M | Sales 2025 * | 1.79B 355M | Capitalization | 1.87B 369M |
---|---|---|---|---|---|
Net income 2024 * | 199M 39.35M | Net income 2025 * | 260M 51.41M | EV / Sales 2024 * | 1.31 x |
Net Debt 2024 * | 220M 43.59M | Net Debt 2025 * | 328M 64.94M | EV / Sales 2025 * | 1.22 x |
P/E ratio 2024 * |
9
x | P/E ratio 2025 * |
7.47
x | Employees | 1,900 |
Yield 2024 * |
2.67% | Yield 2025 * |
3.21% | Free-Float | 16.44% |
Latest transcript on Blau Farmacêutica S.A.
1 day | +1.55% | ||
1 week | +4.37% | ||
Current month | +4.37% | ||
1 month | -12.42% | ||
3 months | -15.92% | ||
6 months | -39.39% | ||
Current year | -35.95% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 87-12-17 | |
Director of Finance/CFO | - | 18-04-30 | |
Roberto Altieri
CMP | Compliance Officer | - | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 61 | - | |
Chief Operating Officer | 58 | - | |
Founder | - | 87-12-17 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 0 M€ | +3.53% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 10.44 | +1.00% | 355 900 |
24-05-07 | 10.51 | +1.55% | 228,800 |
24-05-06 | 10.35 | -1.71% | 228,400 |
24-05-03 | 10.53 | +3.03% | 387,600 |
24-05-02 | 10.22 | +1.49% | 369,300 |
Delayed Quote Sao Paulo, May 07, 2024 at 04:07 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.95% | 369M | |
+33.43% | 700B | |
+27.75% | 569B | |
-5.12% | 358B | |
+19.59% | 330B | |
+4.89% | 287B | |
+16.28% | 236B | |
+6.67% | 202B | |
-8.92% | 197B | |
+4.26% | 161B |
- Stock Market
- Equities
- BLAU3 Stock